Franklin Resources Inc. Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Franklin Resources Inc. lowered its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 17.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 579,636 shares of the company's stock after selling 118,900 shares during the quarter. Franklin Resources Inc. owned 3.86% of Jasper Therapeutics worth $10,903,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Samsara BioCapital LLC grew its stake in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company's stock valued at $10,997,000 after buying an additional 59,642 shares during the last quarter. Braidwell LP purchased a new position in Jasper Therapeutics during the 3rd quarter valued at $9,091,000. Ally Bridge Group NY LLC grew its position in Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after acquiring an additional 180,852 shares during the last quarter. State Street Corp increased its stake in Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company's stock worth $4,042,000 after purchasing an additional 23,564 shares during the period. Finally, Fernwood Investment Management LLC increased its stake in Jasper Therapeutics by 6.9% in the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock worth $995,000 after purchasing an additional 3,427 shares during the period. 79.85% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JSPR. BMO Capital Markets started coverage on Jasper Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. JMP Securities restated a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Evercore ISI reiterated an "outperform" rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. Finally, HC Wainwright restated a "buy" rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Thursday, October 24th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $73.38.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR traded up $0.04 during mid-day trading on Friday, hitting $21.57. The stock had a trading volume of 206,130 shares, compared to its average volume of 175,697. The company has a 50 day moving average of $21.63 and a two-hundred day moving average of $20.69. Jasper Therapeutics, Inc. has a twelve month low of $5.00 and a twelve month high of $31.01. The firm has a market cap of $323.57 million, a PE ratio of -4.55 and a beta of 2.18.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.